• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ:VRTX)

    480.07 -0.18 (-0.04%)
    Streaming Delayed Price Updated: 10:19 AM EDT, Jul 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Vertex Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    67 68 Next >
    News headline image
    Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗
    Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be. 
    Via The Motley Fool
    News headline image
    Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗
    Vertex Pharmaceuticals recently announced its largest-ever acquisition. 
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse ↗
    Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a... 
    Via MarketBeat
    News headline image
    Is This Biotech Stock a Buy Near Its 52-Week High? ↗
    It's been a volatile year for the company, but don't let that scare you away. 
    Via The Motley Fool
    Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗
    Via Chartmill
    News headline image
    Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗
    It is getting acquired by a larger firm in the sector. 
    Via The Motley Fool
    Topics Bonds
    News headline image
    3 Reasons to Buy CRISPR Therapeutics Stock ↗
    The company's innovative qualities may pay rich dividends down the road. 
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗
    Additional blockbuster drugs may be on the horizon. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    1 Momentum Stock to Research Further and 2 Facing Headwinds
    Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
    Via StockStory
    News headline image
    Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
    Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis... 
    Via MarketBeat
    News headline image
    A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
    This new technology could one day significantly expand the market for gene-editing biotechs. 
    Via The Motley Fool
    News headline image
    Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗
    This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate. 
    Via The Motley Fool
    News headline image
    Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗
    The drugmaker is paying up for a new growth engine. Is the price disciplined? 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    3 Cash-Heavy Stocks with Promising Prospects
    In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for t... 
    Via StockStory
    Which S&P500 stocks are showing activity after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher? ↗
    The pharma stock is up around 17% this year. 
    Via The Motley Fool
    News headline image
    While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead ↗
    This big biotech stock doesn't get the hype that SpaceX does. But it could be the smarter bet right now. 
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
    Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value. 
    Via The Motley Fool
    News headline image
    Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗
    Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare? 
    Via The Motley Fool
    News headline image
    Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
    Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. ... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
    Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals... 
    Via Benzinga
    News headline image
    CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
    From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles. 
    Via The Motley Fool
    News headline image
    The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
    The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout. 
    Via MarketBeat
    Topics ETFs
    News headline image
    The Best Stocks to Invest $1,000 in Right Now ↗
    Exploring some of the top bargains in a multi-trillion-dollar industry. 
    Via The Motley Fool
    News headline image
    3 of Wall Street’s Favorite Stocks to Consider Right Now
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
    Via StockStory
    News headline image
    2 Reasons to Like VRTX (and 1 Not So Much)
    Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $452.99. The stock also fell s... 
    Via StockStory
    News headline image
    If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗
    These well-established companies are on track to deliver more growth. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗
    These companies don't typically compete directly with one another, but that might change soon. 
    Via The Motley Fool
    News headline image
    Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
    The opportunity is enormous, but uncertainty remains. 
    Via The Motley Fool
    News headline image
    3 Market-Beating Stocks Worth Investigating
    Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    67 68 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.